Plain-English translation of NCT04381143 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
ASPIRED is testing whether aspirin—a common, inexpensive blood thinner—can help prevent serious heart problems in people with end-stage kidney disease who are on dialysis. Researchers will compare people who take a daily 100 mg aspirin tablet to those who take a placebo (inactive pill) over about 5 years. The study includes 9,000 patients and uses routine dialysis clinic visits to track results.
People on dialysis have a very high risk of heart attacks and strokes, but it's unclear whether this medication can safely reduce those risks in this population. This trial aims to answer that important question so doctors know whether to recommend it for their dialysis patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to take either aspirin or a placebo pill—one tablet by mouth every day. You'll visit your dialysis clinic every six months as part of your normal care, and researchers will collect information about your health during those routine visits. The study will continue for approximately 5 years, and an independent safety team will monitor the results to make sure everyone stays safe.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
China